2 HCV Treatment Articles Links

[Guest guest]

FDA Committee Sets Review Dates for HCV Drugs Boceprevir and Telaprevir

SUMMARY› The U.S. Food and Drug Administration (FDA) announced this week that

the its Antiviral Drugs Advisory Committee will meet at the end of April to

review data on the first eagerly awaited hepatitis C virus (HCV) protease

inhibitors, Merck's boceprevir and Vertex Pharmaceuticals' telaprevir; the

public is invited to attend and give their comments. The committee is expected

to give a recommendation in late May, setting the stage for a full FDA approval

decision this summer.

New Phase 2b Study of Experimental Hepatitis C Vaccine ChronVac-C

SUMMARY› Inovio Pharmaceuticals this week announced that its partner ChronTech

has started a new Phase 2 clinical trial to evaluate an investigational

therapeutic hepatitis C virus (HCV) vaccine candidate known as ChronVac-C. In

early studies the vaccine increased T-cell responses against HCV, suppressed

viral load, and appeared to be safe and well-tolerated.